Venous thromboembolism
Jun 1, 2025, 03:33
Blood Advances Study Reveals Misclassification of Venous Thromboembolism (VTE) Risk
American Society of Hematology shared a post on X:
“Venous thromboembolism (VTE) affects 1 million Americans yearly. A recent study in Blood Advances shows 1 in 3 medical patients had misclassified VTE risk, leading to inappropriate treatment for half. ”
Accurate VTE risk assessment is essential to avoid both under- and overtreatment. This study draws attention to how often patients are misclassified.
Check out the full study here.
Get the latest news on Hemostasis Today.
-
Sep 1, 2026, 09:16Nicolas Gendron: Real-World Data on Danaparoid in Patients with Suspected HIT
-
Sep 1, 2026, 08:24Cristina Chang: The Importance of The New ET Treatments
-
Sep 1, 2026, 07:22Abdul Mannan: ASH 2026 Guidelines – New Treatment Approach for Adult ITP
-
Sep 1, 2026, 07:20Alejandro González Veliz: Silent Atherosclerosis Starts Earlier Than We Think
-
Sep 1, 2026, 07:18Alan Nurden: A New Mechanism Behind Immune Thrombocytopenia
-
Sep 1, 2026, 07:18Susan Shea: New NHLBI Fellowship Supports Thrombinflammation Research
-
Sep 1, 2026, 07:12Sriraman Punniakoti: Pediatric ALL Therapy and Cerebrovascular Thrombosis
-
Sep 1, 2026, 07:04Piotr Czempik: ROTEM in Sepsis-Related Coagulopathy
-
Sep 1, 2026, 07:02Amin Omar Khlifat: Reading the Laboratory Clues to Differentiate Types of Anemia